SEROTONIN AND SEROTONIN-NOREPINEPHRINE SELECTIVE REUPTAKE INHIBITORS IN ANTIMICROBIAL THERAPY: INSIGHTS IN POTENTIAL AND CHALLENGES
REMUNOM · 18.06.2026 · 13 (08) · 1-49
DOI: 10.66104/gk6sh023 ↗Kurz gefasst
Fachartikel in der Zeitschrift REMUNOM, online erschienen am 18.06.2026. Verfasst von Priscila Luiza Mello und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance (AMR) continues to rise among bacterial and fungal pathogens, while the discovery of new anti-infectives remains limited. Drug repurposing provides an opportunity to expand therapeutic options using existing pharmacological and safety data. This narrative review summarizes evidence on the antimicrobial potential of selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) against clinically relevant microorganisms. SSRIs such as sertraline and fluoxetine show bactericidal activity in vitro against Staphylococcus aureus (including MRSA), Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, often synergizing with antibiotics like polymyxin B, ciprofloxacin, and trimethoprim–sulfamethoxazole through efflux pump inhibition, membrane disruption, or interference with energy metabolism. In fungi, SSRIs and SNRIs display fungicidal and antibiofilm effects against Candida spp. (notably C. auris), Cryptococcus neoformans, C. gattii, and filamentous fungi such as Aspergillus spp. and Trichophyton rubrum, with synergism reported alongside fluconazole, amphotericin B, and caspofungin. Proposed mechanisms involve interference with ergosterol biosynthesis, mitochondrial dysfunction, and inhibition of fungal protein synthesis. Despite encouraging in vitro and early in vivo results, clinical translation is limited by pharmacokinetic demands, toxicity, and formulation challenges. SSRIs and SNRIs thus represent a promising yet underexplored antimicrobial strategy warranting further pharmacological and clinical investigation. SSRIs and SNRIs in Antimicrobial Therapy
Zitieren
APA
Mello, P. L., Lodett, G. O., Souza, L. H. N. D., Ferreira, L. E. N., & Scorzoni, L. (2026). SEROTONIN AND SEROTONIN-NOREPINEPHRINE SELECTIVE REUPTAKE INHIBITORS IN ANTIMICROBIAL THERAPY: INSIGHTS IN POTENTIAL AND CHALLENGES. REMUNOM, 13(08), 1-49. https://doi.org/10.66104/gk6sh023
Vancouver
Mello PL, Lodett GO, Souza LHND, Ferreira LEN, Scorzoni L. SEROTONIN AND SEROTONIN-NOREPINEPHRINE SELECTIVE REUPTAKE INHIBITORS IN ANTIMICROBIAL THERAPY: INSIGHTS IN POTENTIAL AND CHALLENGES. REMUNOM. 2026;13(08):1-49. doi:10.66104/gk6sh023
BibTeX
@article{Mello2026,
author = {Mello, Priscila Luiza and Lodett, Giulianna Oliveira and Souza, Luiz Henrique Nunes de and Ferreira, Luiz Eduardo Nunes and Scorzoni, Liliana},
title = {SEROTONIN AND SEROTONIN-NOREPINEPHRINE SELECTIVE REUPTAKE INHIBITORS IN ANTIMICROBIAL THERAPY: INSIGHTS IN POTENTIAL AND CHALLENGES},
journal = {REMUNOM},
year = {2026},
volume = {13},
number = {08},
pages = {1--49},
doi = {10.66104/gk6sh023}
}
EUVIMED